According to AHA/ACC/HRS Atrial Fibrillation Treatment Guidelines: “Patients with AF at risk of stroke should receive oral anticoagulation therapy.”

However...

1 of every 2 patients at risk of stroke did not receive guideline-directed anticoagulation for stroke prevention.

84% of patients with known history of AF were not treated with therapeutic anticoagulation prior to the stroke.

QUANTUM AF is an inpatient quality improvement study aimed at addressing undertreatment of atrial fibrillation (AF) patients at risk of stroke.

- Innovative design, coupling quality improvement within a research framework to allow for more rigorous data collection and analysis.

The analysis of the QI Program will allow us to derive insights beyond just the “movement of the needle.”

- Qualitative findings such as which QI approaches worked, which did not, and why?
- What type of environment contributes to the success of the QI Program?
- What study activities are associated with an increase in appropriate anticoagulation?

This is NOT a patient-level clinical trial. The intervention being studied is the QI Program conducted at the institutional level. IRB review will be required.

30-day readmission rate for AF patients is 18%.

For More Information
Visit our website: www.quantum-af.com
Call us: 704.816.6062
Email us: quantum-af@premierinc.com

A Janssen Scientific Affairs, LLC-sponsored study


Seeking 150 QualityAdvisor Participants for Fair Market Value-Compensated Collaborative
Help us get to the heart of the matter with QUANTUM AF

Each participating facility’s QI Program will be defined locally (not prescribed by Premier).

- Members will collaborate with other participating facilities in the project.
- Premier and the Steering Committee will support participants through resources, educational webinars, coaching and feedback sessions and online dashboards.
- Multi-disciplinary, hospital-wide collaborative approach conducted in the inpatient setting, potentially involving any/all components of the decision and delivery processes.

QUANTUM AF is a drug-agnostic study sponsored by Janssen Scientific Affairs.